1IA
TCRT icon

1834 Investment Advisors’s Alaunos Therapeutics TCRT Stock Holding History

1834 Investment Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13
Closed -$9K – 443
2019
Q4 		$9K Buy
+13
New +$8.95K ﹤0.01% 392

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1834 Investment Advisors's TCRT Position: Q1 2020 in Review

1834 Investment Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2020, closing a stake of 13 shares — an estimated $9K sold.

1834 Investment Advisors first reported a position in TCRT in Q4 2019 and held it in 1 quarter. The position peaked at $9K in Q4 2019. 146 funds tracked by Wall St. Rank hold TCRT as of Q1 2020.

  • 1834 Investment Advisors reported no remaining Alaunos Therapeutics position as of Q1 2020 after selling out during the quarter.
  • 1834 Investment Advisors sold 13 Alaunos Therapeutics shares in Q1 2020, an estimated $9K.
  • 1834 Investment Advisors first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 1 quarter.
  • 1834 Investment Advisors's Alaunos Therapeutics position peaked at $9K in Q4 2019.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2020.

Based on 1834 Investment Advisors's 13F filing for Q1 2020, filed 15 May 2020.